Lancashire and South Cumbria
Formulary
Formulary
9 Nutrition and blood
This chapter of the formulary is under continual development, please let the team know if you have any comments about the contents: mlcsu.lscformulary@nhs.net.
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
09-05-01-01 Calcium supplements
| Calcium Carbonate |
|
Formulary
|
Chewable tablets calcium carbonate 1.25 g (calcium 500 mg or Ca2+ 12.5 mmol) |
|
| Calcium carbonate with calcium lactate gluconate Calvive 1000® Effervescent Tablets |
|
Formulary
|
Effervescent tablets calcium 1000mg (25mmol) |
|
|
| Calcium Gluconate |
|
Formulary
|
Injection 10% (calcium 2.25mmol/10mL)10mL amp |
 MHRA: Calcium chloride, calcium gluconate: potential risk of underdosing with calcium gluconate in severe hyperkalaemia MHRA: Calcium gluconate injection in small-volume glass containers: new contraindications due to aluminium exposure risk |
|
Links
LSCMMG: Bariatric surgery guidelines for prescribing of vitamins and nutritional supplements: Position Statement- LSCMMG: Gluten-Free food products: Position Statement
- LSCMMG: Oral Nutritional Supplements in Primary Care
- LSCMMG: PKU - Prescribing of Multivitamins & Phenylalanine-free amino acid substitutes for adults and children
- MHRA: Calcium chloride, calcium gluconate: potential risk of underdosing with calcium gluconate in severe hyperkalaemia
- MHRA: Calcium chloride, calcium gluconate: potential risk of underdosing with calcium gluconate in severe hyperkalaemia
- MHRA: Calcium gluconate injection in small-volume glass containers: new contraindications due to aluminium exposure risk
- NICE CG32: Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutrition
- NICE NG20: Coeliac disease: recognition, assessment and management
- NICE NG203: Chronic kidney disease: assessment and management
UKMI Q&A: How is acute hypermagnesaemia treated in adults?